Nasdaq · Healthcare
AYTU BIOPHARMA, INC (AYTU)
As-reported financials and recent SEC filings for AYTU BIOPHARMA, INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$66.4M
Net income
$-13.6M
Net margin
-20.4%
Diluted EPS
—
ROE
-71.5%
P/E (TTM)
—
Market cap
—
Debt / equity
0.6×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $66.4M | $65.2M | $107.4M | $96.7M | $65.6M |
| Gross profit | $45.8M | $49.1M | $66.6M | $52.3M | $29.2M |
| Operating income | $-7.8M | $-1.6M | $-17.1M | $-109.9M | $-58.9M |
| Net income | $-13.6M | $-15.8M | $-17.1M | $-108.8M | $-58.3M |
| Diluted EPS | — | — | $-5.11 | $-37.01 | $-19.14 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-25
View on EDGAR →10-Q2026-05-13
View on EDGAR →8-K2026-05-13
View on EDGAR →8-K2026-04-02
View on EDGAR →SCHEDULE 13G/A2026-02-17
View on EDGAR →SCHEDULE 13G/A2026-02-13
View on EDGAR →10-Q2026-02-03
View on EDGAR →8-K2026-02-03
View on EDGAR →Largest Healthcare peers
Go deeper on AYTU
Search AYTU BIOPHARMA, INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.